Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.06 EUR
Change Today -0.023 / -2.13%
Volume 0.0
BDQN On Other Exchanges
Symbol
Exchange
BDQN is not on other exchanges.
As of 2:45 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

biodel inc (BDQN) Snapshot

Open
€1.08
Previous Close
€1.08
Day High
€1.10
Day Low
€1.05
52 Week High
04/2/14 - €2.50
52 Week Low
10/15/14 - €0.92
Market Cap
25.4M
Average Volume 10 Days
1.1K
EPS TTM
--
Shares Outstanding
24.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIODEL INC (BDQN)

Related News

No related news articles were found.

biodel inc (BDQN) Related Businessweek News

No Related Businessweek News Found

biodel inc (BDQN) Details

Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company is conducting a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-123, which has been evaluated in a Phase 2 clinical trial combining recombinant human insulin with its proprietary combination of excipients; and BIOD-531, a concentrated ultra-rapid-acting insulin formulation. The company was founded in 2003 and is headquartered in Danbury, Connecticut.

30 Employees
Last Reported Date: 12/19/14
Founded in 2003

biodel inc (BDQN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $688.4K
Chief Medical Officer
Total Annual Compensation: $437.0K
Chief Administrative Officer, Vice President ...
Total Annual Compensation: $334.2K
Compensation as of Fiscal Year 2014.

biodel inc (BDQN) Key Developments

Biodel Mulls Acquisitions

Biodel Inc. (NasdaqCM:BIOD) is looking for acquisitions. Biodel Inc. has filed a follow-on equity offering and intends to use the net proceeds from this offering for operating costs, capital expenditures and for general corporate purposes, including working capital. Biodel Inc. may also use a portion of the net proceeds to invest in or acquire businesses or technologies that are complementary to their own.

Biodel Inc. Approves Amendment to the Second Amended and Restated Certificate of Incorporation

Biodel Inc. at its annual meeting of stockholders 2015 held on March 17, 2015, approved the amendment to the company's Second Amended and Restated Certificate of Incorporation, as amended, to effect an increase in the number of shares of authorized common stock, par value $0.01 per share, from 62,500,000 shares to 200,000,000 shares.

Biodel Inc. Announces Positive Preliminary Results from Study 6-101, a Phase 1 Clinical Trial

Biodel Inc. announced positive preliminary results from Study 6-101, a Phase 1 clinical trial comparing Biodel's lyophilized glucagon formulation BIOD-961, designed for use in a proprietary Glucagon Emergency Management (GEM) auto-reconstitution device, to Eli Lilly's Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen(R) HypoKit(TM), which are marketed for the treatment of severe hypoglycemia. Study 6-101 was a randomized, single-center, double blind, six-period cross over study in 15 healthy volunteers who received each glucagon administered subcutaneously (SC) and intramuscularly (IM) in a randomized treatment sequence. The objectives of the study were to compare the pharmacokinetic (PK) profiles, the pharmacodynamic (PD, glucose) responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. Overall, PK and PD (glucose response) profiles among all three glucagon formulations were statistically indistinguishable. Although this study was designed as an exploratory comparison of PK and PD profiles, standard regulatory criteria for PK and PD bioequivalence were satisfied when comparing BIOD-961 to Eli Lilly's Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen(R) HypoKit(TM). As expected, nausea was the most common adverse event for all glucagon formulations. The incidence of adverse events was similar among treatments. Biodel formulated BIOD-961 for use in a user-friendly injection device, referred to as the Glucagon Emergency Management (GEM) system. The GEM device is a customized version of an auto-reconstitution syringe developed by Unilife Corporation. The device is specifically designed to address and expand an underserved market currently wrestling with cumbersome glucagon kits that are especially difficult to use and operate during an emergency for the treatment of severe hypoglycemia. This is the first glucagon formulation in development for the treatment of severe hypoglycemia which has demonstrated comparable pharmacokinetic and pharmacodynamic profiles to marketed glucagon formulations. In addition to the pivotal clinical trial, a human factors study is planned for the first half 2015 to compare the usability of the GEM device to the existing manually reconstituted commercial glucagon kits in the hands of representative caregivers, with the final pivotal human factors study expected to be completed by the end of 2015. The company plans to request an end-of-Phase 2 meeting with the FDA in the second calendar quarter of 2015 and submit the NDA in mid-2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDQN:GR €1.06 EUR -0.023

BDQN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BDQN.
View Industry Companies
 

Industry Analysis

BDQN

Industry Average

Valuation BDQN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODEL INC, please visit www.biodel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.